TJ08

Research use only, not for human use.

TJ08 is a 1,2,5-trisubstituted benzimidazole derivative with anticancer properties that effectively induces G1/S phase blockade while promoting apoptotic effects in a variety of cancer cells.

TJ08, a 1,2,5-trisubstituted benzimidazole derivative, efficiently induces G1/S phase arrest and promotes apoptosis in various cancer cells. TJ08 is an anticancer agent.

Cell Proliferation Assay Cell Line:Human leukemic cancer cells (Jurkat, K562, and Molt4), human cervical cancer cells (HeLa), human colorectal carcinoma cells (HCT116), and human pancreatic ductal adenocarcinoma (MIAPaCa-2)Concentration:0-20 μM Incubation Time:48 and 72 h Result:Showed effective against various cells with IC50s of 1.88 μM, 1.89 μM, 2.05 μM, 2.11 μM, 3.04 μM, and 3.82 μM against Jurkat, K562, MOLT-4, HeLa, HCT116, and MIA PaCa-2 cancer cell lines, respectively. Apoptosis Analysis Cell Line:Jurkat cells Concentration:1, 5, 10 μM Incubation Time:24 h Result:Induced cell death by apoptosis, not by necrosis, in a concentration-dependent manner.Cell Cycle AnalysisCell Line:Jurkat cells Concentration:1, 5, 10 μM Incubation Time:24 h Result:Cauesd the accumulation of cells at the S phase in a concentration-dependent manner followed by increased accumulation of a sub-G1 population of cells.Western Blot Analysis Cell Line:Jurkat cells Concentration:1, 5, 10 μM Incubation Time:24 h Result:Caused the upregulation of cleaved caspase and downregulation of antiapoptotic BCl2 proteins.

——

——

Apoptosis

Apoptosis

Apoptosis

——

——

2924274-19-9

405.38

C22H16FN3O4

>98% (HPLC)

——

O=C(C1=CC=C2C(N=C(N2CC3=CC=CC=C3)C4=CC([N+]([O-])=O)=C(F)C=C4)=C1)OC

——

(-20℃)

With Ice Pack

≥ 2 years